Optimi Health to Export MDMA and Psilocybin Capsules to Australia

LOS ANGELES- a Health Canada licensed GMP psychedelics pharmaceutical manufacturer, announced it has received an import permit from Mind Medicine Australia (MMA) to supply its GMP MDMA and psilocybin capsules to approved psychiatrists under Australia’s Authorised Prescriber Scheme.

Mind Medicine Australia has been a partner of Optimi since February 2023 and played a pivotal role in the rescheduling of MDMA for PTSD treatment and psilocybin for treatment-resistant depression (TRD). This regulatory change allows these substances to be prescribed by Authorised Prescribers in Australia, opening new therapeutic avenues.

“Australian psychiatrists can now prescribe Optimi’s MDMA and psilocybin capsules for therapeutic use in patients, which is a very humbling achievement,” said JJ Wilson, Co-Founder and Chair of Optimi Health. “This initial export will fulfill early demand from Authorised Prescribers in Australia and is a significant milestone that our shareholders should take immense pride in. None of this would have been achievable without our partners, Mind Medicine Australia.”

Optimi has developed a secure Prescriber Portal, launching in June 2024, to support the network of more than 2,800 Australian psychiatrists. This portal will offer pre-authorized access to detailed information on the import and export process and insights into Optimi’s MDMA and psilocybin capsules.

“We are thrilled to reach this pivotal moment, made possible by the tremendous hard work and dedication from both our team and our partners at Optimi Health,” said Peter Hunt, Chair of Mind Medicine Australia. “Securing the import permits to receive Optimi’s MDMA and psilocybin capsules marks a significant step forward in our mission. We are excited to be on this journey with Optimi of helping Australians who are suffering from major mental illnesses to gain access to these transformative therapies. Together, we are ready to make a real difference in the lives of so many patients.”

Focus on Accessibility and Affordability

Mind Medicine Australia aims to provide psychedelic-assisted therapies at the most cost-effective rates. Optimi CEO Bill Ciprick emphasized, “Affordability and accessibility is the backbone of our partnership, and we intend to deliver on that commitment by offering MDMA and psilocybin capsules at the most cost-effective price in the market.”

Mind Medicine Australia’s certificate in psychedelic-assisted therapies has graduated over 350 professionals, equipping them with the skills to facilitate these therapies safely and effectively. Currently, there are 10 Authorised Prescribers in Australia, with over 40 psychiatrists having completed MMA’s training program. An additional 20 are expected to graduate by the end of 2024, indicating a potential increase in Authorised Prescribers and support therapists in the coming months.